K Harada1, H Miyake, Y Kusuda, M Fujisawa. 1. Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Abstract
PURPOSE: The objective of this study was to investigate the mechanism mediating the acquisition of a resistant phenotype to sorafenib in renal cell carcinoma (RCC). METHODS: A parental mouse RCC cell line, RenCa (RenCa/P), was continuously exposed to increasing doses of sorafenib, and a cell line resistant to sorafenib (RenCa/R), showing an approximately sixfold higher IC(50) than that of RenCa/P, was established. Changes in the expression of several molecules in these cell lines following sorafenib treatment were evaluated by western blotting, and the effects of sorafenib treatment on the in vivo growth patterns were compared. RESULTS: There were no significant differences in sensitivities to potential agents against RCC between RenCa/P and RenCa/R. Among several apoptosis-related proteins, the expression of clusterin in RenCa/R was significantly greater than that in RenCa/P. Following treatment with sorafenib, the expression level of phosphorylated p44/42 mitogen-activated protein kinase (MAPK) in RenCa/P, but not that in RenCa/R, was significantly decreased. Furthermore, additional treatment with a specific inhibitor of the MAPK signaling pathway significantly increased the sensitivity of RenCa/R to sorafenib, but not that of RenCa/P. There was no significant difference between the in vivo growth patterns of RenCa/P and RenCa/R in mice without sorafenib treatment; however, the growth inhibitory effect of sorafenib on the RenCa/P tumor was significantly greater than that on the RenCa/R tumor. CONCLUSIONS: These findings suggest that the upregulation of clusterin and continuous activation of the MAPK pathway during sorafenib treatment may be involved in the acquisition of a resistance to sorafenib in RCC.
PURPOSE: The objective of this study was to investigate the mechanism mediating the acquisition of a resistant phenotype to sorafenib in renal cell carcinoma (RCC). METHODS: A parental mouseRCC cell line, RenCa (RenCa/P), was continuously exposed to increasing doses of sorafenib, and a cell line resistant to sorafenib (RenCa/R), showing an approximately sixfold higher IC(50) than that of RenCa/P, was established. Changes in the expression of several molecules in these cell lines following sorafenib treatment were evaluated by western blotting, and the effects of sorafenib treatment on the in vivo growth patterns were compared. RESULTS: There were no significant differences in sensitivities to potential agents against RCC between RenCa/P and RenCa/R. Among several apoptosis-related proteins, the expression of clusterin in RenCa/R was significantly greater than that in RenCa/P. Following treatment with sorafenib, the expression level of phosphorylated p44/42 mitogen-activated protein kinase (MAPK) in RenCa/P, but not that in RenCa/R, was significantly decreased. Furthermore, additional treatment with a specific inhibitor of the MAPK signaling pathway significantly increased the sensitivity of RenCa/R to sorafenib, but not that of RenCa/P. There was no significant difference between the in vivo growth patterns of RenCa/P and RenCa/R in mice without sorafenib treatment; however, the growth inhibitory effect of sorafenib on the RenCa/P tumor was significantly greater than that on the RenCa/R tumor. CONCLUSIONS: These findings suggest that the upregulation of clusterin and continuous activation of the MAPK pathway during sorafenib treatment may be involved in the acquisition of a resistance to sorafenib in RCC.
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Rupal S Bhatt; Xiaoen Wang; Liang Zhang; Michael P Collins; Sabina Signoretti; David C Alsop; S Nahum Goldberg; Michael B Atkins; James W Mier Journal: Mol Cancer Ther Date: 2010-08-10 Impact factor: 6.261
Authors: Mototsugu Muramaki; Alan So; Norihiro Hayashi; Richard Sowery; Hideaki Miyake; Masato Fujisawa; Martin E Gleave Journal: BJU Int Date: 2008-10-24 Impact factor: 5.588
Authors: Liang Zhang; Manoj Bhasin; Rachel Schor-Bardach; Xiaoen Wang; Michael P Collins; David Panka; Prabhakar Putheti; Sabina Signoretti; David C Alsop; Towia Libermann; Michael B Atkins; James W Mier; S Nahum Goldberg; Rupal S Bhatt Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Leticia Serrano-Oviedo; Marta Ortega-Muelas; Jesús García-Cano; María Ll Valero; Francisco J Cimas; Raquel Pascual-Serra; Diego M Fernandez-Aroca; Olga Roche; María J Ruiz-Hidalgo; Borja Belandia; José M Giménez-Bachs; Antonio S Salinas; Ricardo Sanchez-Prieto Journal: PLoS One Date: 2018-07-26 Impact factor: 3.240